ReviewFrontiers in bioengineering and biotechnology2025
Emerging biomaterials and bio-nano interfaces in pulmonary hypertension therapy: transformative strategies for personalized treatment.
Review in Frontiers in bioengineering and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Exosome-Inspired Nanocarriers in Cancer Therapy: Bio-Derived Nanotechnology Meets Nano Drug Delivery.International journal of nanomedicine · 2026Review
- Smart biomaterials: as active immune modulators to shape pro-regenerative microenvironments.Frontiers in cell and developmental biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary hypertension (PH) is still an aggressive and progressive illness with vascular remodeling and right heart failure despite the therapeutic advances made in the recent past. Biomaterials offer an attractive route to break the current therapeutic paradigms by inducing vascular repair, facilitating drug targeting, and allowing dynamic regeneration of tissue. This review taking an integrated approach investigates the revolutionary role played by novel biomaterials and bio-nano interfaces in PH treatment. We classify and evaluate several classes of biomaterial platforms including natural polymers, scaffolds based on synthetic polymers, extracellular vesicles (EVs), and stimulus-responsive systems with an emphasis on both underlying mechanisms and clinical relevance. We further address the progress made in artificial intelligence (AI)-based biomaterials and in integrating multi-omics tools to provide patient-tailored therapy. We finally touch on the ongoing limitations and enumerate future directions required to take forward biomaterial-based therapies towards clinical reality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.